AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/article-1G1-188043249/protherics-plc-announces-research.html" title="Facts and information about Protherics PLC announces research update.">Protherics PLC announces research update.</a>
Close
Set up an RSS feed that alerts you when new articles from Chemical Business Newsbase are available.
Frequently asked questions about RSS feeds
Protherics PLC announces research update.
Protherics PLC announces the initiation of a Phase IIa proof-of-concept study of Prolarix, a targeted prodrug chemotherapy being developed for the treatment of primary liver cancer (hepatocellular carcinoma or HCC). This follows promising data from a Phase I study of Prolarix, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA on 2 Jun 2008. The Phase IIa proof-of-concept study is designed to evaluate tumour …
Related articles from newspapers, magazines, journals, and more
-
- CeNeS Pharmaceuticals plc announces successful results from its Phase IIa...
-
News wire article from: Asia Africa Intelligence Wire
June 8, 2005
700+ words
-
- BTG plc commences Phase IIa study of Pleneva for multiple sclerosis.
-
News wire article from: Chemical Business Newsbase
January 21, 2010
700+ words
-
- BTG plc: AstraZeneca PLC to progress CytoFab into Phase IIb study.
-
News wire article from: Chemical Business Newsbase
July 29, 2009
700+ words
